Loading
There are several different PD-L1 tests, each tied to a different drug, and they disagree. A single digitally calibrated scale would let any lab's result be translated into any drug's cut-off.
22C3, SP263, 28-8 and SP142 assays, with tumour proportion score, combined positive score and immune-cell scoring, produce different positivity for the same tumour. The Blueprint project showed partial concordance. A quantitative digital pathology reference (stain intensity and cell counts calibrated on shared reference materials) could express each assay on a common scale, so a lab running one assay could report validated equivalents for the cut-offs used in each drug label.
Shares Public gold-standard datasets for validating every cancer biomarker test, PathAI, Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Paige AI.
Shares PathAI, Paige AI, Digital pathology & AI, Histopathology & immunohistochemistry.
Shares PathAI, Paige AI, Digital pathology & AI.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Digital pathology & AI, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised, PD-L1.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Histopathology & immunohistochemistry, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised, PD-L1.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Histopathology & immunohistochemistry, Biomarkers are not validated or standardised.